Myelodysplastic Syndrome Clinical Trial

Collection of Samples From Patients With MDS

Summary

The purpose of this study is to collect information and bone marrow, blood, saliva, cheek cells and skin to be used in the laboratory to assist the sponsor in identifying a new way of treating MDS.

View Full Description

Full Description

Goals of the study:

The purpose of this study is to collect the blood and marrow samples, and non-involved fibroblasts, that are required to identify the unique, personalized array of mutation-driven neoantigens that are expressed by the subject's MDS cells and to assess the feasibility of immunizing and expanding one or more of the patient's T cells ex vivo for investigation of their use as adoptive cellular immunotherapy.

View Eligibility Criteria

Eligibility Criteria

Patients must meet the following initial inclusion criteria:

Diagnosis or suspected diagnosis of MDS or CCUS
Age 18 or older

Patient exclusion criteria:

Currently receiving or within 3 months has received hypomethylating agent(s), lenalidomide, cytotoxic agents, or within the previous 4 weeks corticosteroids > 5 mg prednisone daily or any other immunosuppressants
Previous allogenic transplant
Inability to provide consent
Prisoners

Study is for people with:

Myelodysplastic Syndrome

Estimated Enrollment:

24

Study ID:

NCT03072498

Recruitment Status:

Unknown status

Sponsor:

PersImmune, Inc

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

University of California, Irvine
Irvine California, 92868, United States More Info
Chao Family Comprehensive Cancer Center
Contact
877-827-8839
[email protected]
Jessica Limson
Contact
7145096233
[email protected]
Deepa Jeyakumar, M.D.
Principal Investigator
University of California San Diego
La Jolla California, 92093, United States More Info
Colin McCarthy
Contact
858-534-8127
[email protected]
Kimberly Aguilar
Contact
858-534-5201
[email protected]
Rafael Bejar, M.D., Ph.D.
Principal Investigator
Tiffany Tanaka, M.D.
Sub-Investigator

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Estimated Enrollment:

24

Study ID:

NCT03072498

Recruitment Status:

Unknown status

Sponsor:


PersImmune, Inc

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider